- Home
- PRPH vs MTVA Comparison
PRPH vs MTVA Comparison
Compare PRPH & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- MTVA
- Stock Information
- Founded
- PRPH 1989
- MTVA 2014
- Country
- PRPH United States
- MTVA United States
- Employees
- PRPH N/A
- MTVA N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- PRPH Health Care
- MTVA
- Exchange
- PRPH Nasdaq
- MTVA NYSE
- Market Cap
- PRPH 15.2M
- MTVA 14.3M
- IPO Year
- PRPH 1997
- MTVA N/A
- Fundamental
- Price
- PRPH $0.43
- MTVA $0.70
- Analyst Decision
- PRPH
- MTVA Strong Buy
- Analyst Count
- PRPH 0
- MTVA 2
- Target Price
- PRPH N/A
- MTVA $7.50
- AVG Volume (30 Days)
- PRPH 4.1M
- MTVA 110.1K
- Earning Date
- PRPH 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- PRPH N/A
- MTVA N/A
- EPS Growth
- PRPH N/A
- MTVA N/A
- EPS
- PRPH N/A
- MTVA N/A
- Revenue
- PRPH $5,845,000.00
- MTVA N/A
- Revenue This Year
- PRPH $221.82
- MTVA N/A
- Revenue Next Year
- PRPH N/A
- MTVA N/A
- P/E Ratio
- PRPH N/A
- MTVA N/A
- Revenue Growth
- PRPH N/A
- MTVA N/A
- 52 Week Low
- PRPH $0.22
- MTVA $0.60
- 52 Week High
- PRPH $3.64
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- PRPH 62.32
- MTVA N/A
- Support Level
- PRPH $0.32
- MTVA N/A
- Resistance Level
- PRPH $0.46
- MTVA N/A
- Average True Range (ATR)
- PRPH 0.03
- MTVA 0.00
- MACD
- PRPH 0.01
- MTVA 0.00
- Stochastic Oscillator
- PRPH 75.57
- MTVA 0.00
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.